Burden of influenza B virus infection and considerations for clinical management
Hassan Zaraket, Aeron C Hurt, Barry Clinch, Ian Barr, Nelson Lee
ANTIVIRAL RESEARCH | ELSEVIER | Published : 2021
Influenza B viruses cause significant morbidity and mortality, particularly in children, but the awareness of their impact is often less than influenza A viruses partly due to their lack of pandemic potential. Here, we summarise the biology, epidemiology and disease burden of influenza B, and review existing data on available antivirals for its management. There has long been uncertainty surrounding the clinical efficacy of neuraminidase inhibitors (NAIs) for influenza B treatment. In this article, we bring together the existing data on NAIs and discuss these alongside recent large randomised controlled trial data for the new polymerase inhibitor baloxavir in high-risk influenza B patients. ..View full abstract
Awarded by Australian Government Department of Health
The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health (gs:_501100003921). Third-party medical writing assistance, under the direction of the authors, was provided by John Bett, PhD, of Gardiner-Caldwell Communications and was funded by F. Hoffmann-La Roche Ltd.